We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Notice for vosoritide (BioMarin Pharmaceutical Australia Pty Ltd)
Active ingredients
vosoritide
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of achondroplasia in patients less than 2 years of age whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing
Therapeutic area
Inherited bone disorder